Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis

Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2(+) breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action (MOA) remains incompletely understood. Past stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsao, Li-Chung, Crosby, Erika J., Trotter, Timothy N., Wei, Junping, Wang, Tao, Yang, Xiao, Summers, Amanda N., Lei, Gangjun, Rabiola, Christopher A., Chodosh, Lewis A., Muller, William J., Lyerly, Herbert Kim, Hartman, Zachary C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986081/
https://www.ncbi.nlm.nih.gov/pubmed/35167491
http://dx.doi.org/10.1172/jci.insight.155636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986081/
https://www.ncbi.nlm.nih.gov/pubmed/35167491
http://dx.doi.org/10.1172/jci.insight.155636

Ejemplares similares